Analystreport

Pluristem Therapeutics, Inc. (NASDAQ: PSTI) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $2.00 price target on the stock.

Pluristem Therapeutics, Inc.  (PSTI) 
Last pluristem therapeutics, inc. earnings: 2/6 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: pluristem.com